Advertisement

Pneumo News

, Volume 10, Issue 2, pp 31–40 | Cite as

Genetische Ursache einer COPD

Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie

  • Sebastian Fähndrich
  • Nikolas Bernhard
  • Philipp Lepper
  • Robert Bals
cme fortbildung
  • 66 Downloads

Zusammenfassung

Die chronisch obstruktive Lungenerkrankung (COPD) ist eine durch inhalative Noxen hervorgerufene chronische Erkrankung, deren Phänotyp neben Umwelteinflüssen auch durch genetische Ursachen wie einem Alpha-1-Antitrypsin(AAT)-Mangel beeinflusst wird, eine Genotypisierung kann mittels Polymerasekettenreaktion und Sequenzierung erfolgen. Um eine Progression der Erkrankung zu verlangsamen, kann AAT substituiert werden.

Literatur

  1. 1.
  2. 2.
    Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. 1963. COPD. 2013;10 Suppl 1:3–8CrossRefGoogle Scholar
  3. 3.
    Konietzko N. [How Carl-Bertil Laurell and Sten Eriksson detected the alpha-1-antitrypsin deficiency 50 years ago and what then came—a somewhat headstrong and personal retrospection]. Pneumologie. 2013;67(10):562–6CrossRefGoogle Scholar
  4. 4.
    Blanco I, de Serres FJ, Fernandez-Bustillo E et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J. 2006;27(1):77–84CrossRefGoogle Scholar
  5. 5.
    Lomas DA, and Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax. 2004;59(6):529–35CrossRefGoogle Scholar
  6. 6.
    Greene CM, McElvaney NG. Z alpha-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther. 2010;1(5):94–101CrossRefGoogle Scholar
  7. 7.
    Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103(8):2136–41; quiz 42CrossRefGoogle Scholar
  8. 8.
    Kamimoto T, Shoji S, Hidvegi T et al. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem. 2006;281(7):4467–76CrossRefGoogle Scholar
  9. 9.
    Hidvegi T, Mirnics K, Hale P et al. Regulator of G Signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant alpha1-antitrypsin Z in the classical form of alpha1-antitrypsin deficiency. J Biol Chem. 2007;282(38):27769–80CrossRefGoogle Scholar
  10. 10.
    Perlmutter DH. Clinical manifestations of alpha 1-antitrypsin deficiency. Gastroenterol Clin North Am. 1995;24(1):27–43PubMedGoogle Scholar
  11. 11.
    Campbell EJ, Campbell MA, Boukedes SS et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest. 1999;104(3):337–44CrossRefGoogle Scholar
  12. 12.
    Stockley RA. Alpha 1-antitrypsin: more than just deficiency. Thorax. 2004;59(5):363–4CrossRefGoogle Scholar
  13. 13.
    DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004;59(3):259–64CrossRefGoogle Scholar
  14. 14.
    Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59(5):441–5CrossRefGoogle Scholar
  15. 15.
    Hersh CP, Dahl M, Ly NP et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59(10):843–9CrossRefGoogle Scholar
  16. 16.
    Brantly ML, Paul LD, Miller BH et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138(2):327–36CrossRefGoogle Scholar
  17. 17.
    Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency—a model for conformational diseases. N Engl J Med. 2002;346(1):45–53CrossRefGoogle Scholar
  18. 18.
    Stoller JK, Snider GL, Brantly ML et al. [American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency]. Pneumologie. 2005;59(1):36–68CrossRefGoogle Scholar
  19. 19.
    Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749–57CrossRefGoogle Scholar
  20. 20.
    Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986;314(12):736–9.CrossRefGoogle Scholar
  21. 21.
    Nelson DR, Teckman J, Di Bisceglie AM et al. Diagnosis and management of patients with alpha1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol. 2012;10(6):575–80CrossRefGoogle Scholar
  22. 22.
    Bowlus CL, Willner I, Zern MA et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005;3(4):390–6CrossRefGoogle Scholar
  23. 23.
    Silverman EK, Pierce JA, Province MA et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989;111(12):982–91CrossRefGoogle Scholar
  24. 24.
    Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994;49(7):695–8CrossRefGoogle Scholar
  25. 25.
    Parr DG, Stoel BC, Stolk J et al. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170(11):1172–8CrossRefGoogle Scholar
  26. 26.
    Gross B, Grebe M, Wencker M et al. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology. 2009;218(4):370–5CrossRefGoogle Scholar
  27. 27.
    Mahr AD, Edberg JC, Stone JH et al. Alpha(1)-antitrypsin deficiency-related alleles Z and S and the risk of Wegener’s granulomatosis. Arthritis Rheum. 2010;62(12):3760–7CrossRefGoogle Scholar
  28. 28.
    Stoller JK, Sandhaus RA, Turino G et al. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989–94CrossRefGoogle Scholar
  29. 29.
    Greulich T, Ottaviani S, Bals R et al. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(9):1400–8CrossRefGoogle Scholar
  30. 30.
    American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900CrossRefGoogle Scholar
  31. 31.
    Bostrom S, Nilsson I. Telescopic suction tube for microsurgery. Acta Neurochir (Wien). 1992;118(3-4):162–3CrossRefGoogle Scholar
  32. 32.
    Costa X, Jardi R, Rodriguez F et al. Simple method for alpha1-antitrypsin deficiency screening by use of dried blood spot specimens. Eur Respir J. 2000;15(6):1111–5CrossRefGoogle Scholar
  33. 33.
    McElvaney NG, Burdon J, Holmes M et al. Long-term efficacy and safety of a1 proteinase inhibitor treatment for emphysema caused by severe a1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017 Jan;5(1):51–60CrossRefGoogle Scholar
  34. 34.
    Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365(9478):2225–36CrossRefGoogle Scholar
  35. 35.
    Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990;85(5):1343–52CrossRefGoogle Scholar
  36. 36.
    Ferrarotti I, Thun GA, Zorzetto M et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax. 2012;67(8):669–74CrossRefGoogle Scholar
  37. 37.
    Wewers MD, Casolaro MA, Sellers SE et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–62CrossRefGoogle Scholar
  38. 38.
    Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax. 2004;59(8):708–12CrossRefGoogle Scholar
  39. 39.
    Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260–3CrossRefGoogle Scholar
  40. 40.
    Tomashefski JF Jr., Crystal RG, Wiedemann HP et al. The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: findings of the Death Review Committee of the national registry for individuals with Severe Deficiency of Alpha-1 Antitrypsin. Hum Pathol. 2004;35(12):1452–61CrossRefGoogle Scholar
  41. 41.
    Wencker M, Fuhrmann B, Banik N et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737–44CrossRefGoogle Scholar
  42. 42.
    Chapman KR, Stockley RA, Dawkins C et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6(3):177–84CrossRefGoogle Scholar
  43. 43.
    Dowson LJ, Guest PJ, Hill SL et al. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17(6):1097–104CrossRefGoogle Scholar
  44. 44.
    Dawkins PA, Dowson LJ, Guest PJ et al. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax. 2003;58(12):1020–6CrossRefGoogle Scholar
  45. 45.
    Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468–72CrossRefGoogle Scholar
  46. 46.
    Dirksen A, Piitulainen E, Parr DG et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345–53CrossRefGoogle Scholar
  47. 47.
    Chapman KR, Burdon JG, Piitulainen E et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–8CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Sebastian Fähndrich
    • 1
  • Nikolas Bernhard
    • 1
  • Philipp Lepper
    • 1
  • Robert Bals
    • 1
  1. 1.Klinik für Innere Medizin V - Pneumologie, Allergologie, Beatmungs- und UmweltmedizinUniversitätsklinikum des SaarlandesHomburg/SaarDeutschland

Personalised recommendations